Celecoxib : a review of its use in the management of arthritis and acute pain.

Celecoxib : a review of its use in the management of arthritis and acute pain. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Celecoxib : a review of its use in the management of arthritis and acute pain. Abstract Text:

James E Frampton,Gillian M Keating,James E Frampton,Gillian M Keating,James E Frampton,Gillian M Keating,

Celecoxib (Celebrex((R))), the first cyclo-oxygenase (COX) 2-selective inhibitor (coxib) to be introduced into clinical practice, has been available for almost a decade. It is approved in one or more countries worldwide for the relief of the signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (in patients aged >/=2 years) and ankylosing spondylitis (AS), the management of acute pain in adults, the treatment of primary dysmenorrhoea and the reduction in the number of adenomatous colorectal polyps in familial adenomatous polyposis.Celecoxib remains an effective and useful altenative to nonselective NSAIDs in the treatment of acute or chronic musculoskeletal pain. In the latter setting, it offers the prospect of improved gastrointestinal (GI) tolerability and, in patients not taking aspirin for cardioprophylaxis, a GI safety advantage. Currently available evidence of an increase in cardiovascular (CV) risk with celecoxib is inconsistent; any increase in risk is likely to be small and similar to that with nonselective NSAIDs. As with all NSAIDs, the potential GI, CV and renal risks of celecoxib must be weighed against the potential benefits in each individual; it is a rational choice for patients at low CV risk who require NSAID therapy, especially those at increased risk of NSAID-induced GI toxicity, but also those unresponsive to, or intolerant of, other NSAIDs. If selected, celecoxib, like all NSAIDs, should be used at the lowest effective dose for the shortest possible duration.

Celecoxib : a review of its use in the management of arthritis and acute pain. Publishing Authors By Initials

JE Frampton,GM Keating,JE Frampton,GM Keating,JE Frampton,GM Keating,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Celecoxib : a review of its use in the management of arthritis and acute pain. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Drugs

VOLUME: 67

Page Numbers: 2433-72

Journal Abbreviation: Drugs

ISSN: 0012-6667

DAY: 6

MONTH: 11

YEAR: 2007

Celecoxib : a review of its use in the management of arthritis and acute pain. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7600076

Celecoxib : a review of its use in the management of arthritis and acute pain. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Celecoxib : a review of its use in the management of arthritis and acute pain. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Celecoxib : a review of its use in the management of arthritis and acute pain.

AFFILIATION: Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA.

Country: New Zealand

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Drugs

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Celecoxib : a review of its use in the management of arthritis and acute pain Related Publications

• Activin-betaA signaling is required for zebrafish fin regeneration.
• Campuses of the LACC.
• Celecoxib : a review of its use in the management of arthritis and acute pain.
• Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment.
• Colesevelam: a review of its use in hypercholesterolemia.
• Computing van der Waals energies in the context of the rotamer approximation.
• Coupling molecular beacons to barcoded metal nanowires for multiplexed, sealed chamber DNA bioassays.
• Coverage and prior authorization of psychotropic drugs under Medicare Part D.
• Deferasirox : a review of its use in the management of transfusional chronic iron overload.
• Differences in hospice care between home and institutional settings.
• Distance-dependent emission from dye-labeled oligonucleotides on striped Au/Ag nanowires: effect of secondary structure and hybridization efficiency.
• Dr. Tom Lawrence: a life in chiropractic.
• E14 Therapy for CLL: current approach, future trends.
• Gene expression analysis of zebrafish heart regeneration.
• Maraviroc.
• Metallic barcodes for multiplexed bioassays.
• Methods for simulating the dynamics of complex biological processes.
• Modeling backbone flexibility to achieve sequence diversity: the design of novel alpha-helical ligands for Bcl-xL.
• Monoclonal antibodies in chronic lymphocytic leukemia.
• On-beam synchrony in the cerebellum as the mechanism for the timing and coordination of movement.
• One size doesn't fit all.
• Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair.
• Quantification of the neurotoxic beta-carboline harmane in barbecued/grilled meat samples and correlation with level of doneness.
• Revision anterior cruciate ligament reconstruction: timing of surgery and the incidence of meniscal tears and degenerative change.
• Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type.
• Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease.
• Silica-coated, Au/Ag striped nanowires for bioanalysis.
• The Homewood influence in Canada and beyond.
• Transcriptional profiling of caudal fin regeneration in zebrafish.
• Using performance data to identify preferred hospitals.